Welcome!

News Feed Item

MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind® and future technology development opportunities were discussed and user’s validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 – 22, 2014.

The poster presentations reviewed clinical data derived from practice and clinical settings that highlighted how MelaFind has helped dermatologists in the assessment of clinically ambiguous pigmented skin lesions in various patients including young adults, an area of growing concern, and those with atypical mole syndrome. To view the posters and their accompanying abstract please click here.

The poster authored by Dr. Darrell Rigel, titled Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device for Melanoma, and outlined below was named Poster of the Day on the first day of the conference.

Highlights of the studies and the data shown in the poster presentations are as follows:

Physical Properties, Novel Features and Clinical Validation of a Multispectral Digital Skin Lesion Analysis Device (MSDSLA) for Melanoma Detection - Darrell S. Rigel, MD, MS NYU School of Medicine, New York, NY; Laura Ferris, MD, PhD, University of Pittsburgh. Pittsburgh, PA; Arthur Sober, MD, Harvard University, Boston, MA; Clay J. Cockerell, MD, University of Texas Southwestern, Dallas, TX

  • Retrospective data from the MelaFind pivotal study was used to investigate the MelaFind multispectral images and classifier score result as a tool to differentiate cutaneous melanoma from other pigments skin lesions.
  • Results showed the average classifier scores of melanomas, high-grade lesions, non-melanoma skin cancers, and histologically benign nevi were 3.5, 2.7, 2.6 and 1.6 respectively.
  • Further results showed an increase in the mean classifier score result with each additional clinical characteristic present in the lesion.

Assessing the Predictive Probability of Melanoma and Other High Risk Pigmented Lesions Using Data Provided by a Multispectral digital Skin Lesion Analysis Device - Jane Yoo, MD, MPP, Dept. of Dermatology, Albert Einstein School of Medicine, Bronx, NY; Natalie Tucker, BS, MELA Sciences, Irvington, NY; Darrell S. Rigel, MD, MS, Dept. of Dermatology, NYU School of Medicine, NYC, NY

  • A risk prediction model was built to assess the predictive probability of melanoma or a high-risk lesion for consideration for biopsy based on data obtained from MelaFind.
  • Results show a potential quantitative predictive capacity for presence of melanoma and other high risk pigmented lesions using the MelaFind device.

In addition to presenting data from the four studies, MELA Sciences held its third Clinical Advisory Meeting for current and prospective MelaFind users and thought leaders. In attendance was Dr. Antonanella Calame, dermatologist, dermatopathologist and medical director of Compass Dermatology and Dermatopathology in La Jolla, CA. Dr. Calame, a user of MelaFind, said, “As dermatologists, one of our most important goals is diagnosing melanoma, the deadliest form of skin cancer, at its earliest and most curable stage. The MelaFind system’s images and data analysis tools help dermatologists with one of the most challenging questions we face each day when evaluating clinically ambiguous pigments skin lesions: “Is this lesion atypical enough for me to remove and investigate further via histology?” MelaFind’s analysis of a lesion’s architectural structure gives us access to new information deeper into the skin, where the human eye cannot see, and helps us answer this critical question, improving overall outcomes for both patient and clinician. These tools are available for the first time in medicine and MelaFind is just the beginning. If patient outcomes are our foremost concern, adoption of such technologies should be widespread and soon become part of the standard of care.”

The Winter Clinical Dermatology Conference was conducted over four days and had nearly 400 participants from various fields of dermatology, medical and cosmetic. In discussing the Advances in the Diagnosis of Melanoma, Dr. Laura Ferris credited MelaFind as an important instrument in helping to detect melanoma.

Please follow us:

         

 

Twitter:

@MELASciencesIR or @MelaFind

 

StockTwits:

@MELASciencesIR

 

Facebook:

www.facebook.com/MelaFind

About MELA Sciences, Inc. www.melasciences.com

MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The flagship product is MelaFind®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis. MelaFind® uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as “seeks,” “look forward,” and “there seems” that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you ...
Virtualization over the past years has become a key strategy for IT to acquire multi-tenancy, increase utilization, develop elasticity and improve security. And virtual machines (VMs) are quickly becoming a main vehicle for developing and deploying applications. The introduction of containers seems to be bringing another and perhaps overlapped solution for achieving the same above-mentioned benefits. Are a container and a virtual machine fundamentally the same or different? And how? Is one techn...
My team embarked on building a data lake for our sales and marketing data to better understand customer journeys. This required building a hybrid data pipeline to connect our cloud CRM with the new Hadoop Data Lake. One challenge is that IT was not in a position to provide support until we proved value and marketing did not have the experience, so we embarked on the journey ourselves within the product marketing team for our line of business within Progress. In his session at @BigDataExpo, Sum...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...